Alcohol is metabolised into a toxic and carcinogenic substance called acetaldehyde which is then converted to harmless acetate. The first step is controlled by the ADH1B enzyme and the second by ALDH2 enzyme.
The ADH1B (rs1229984) SNP changes the enzyme structure and increases its ability to convert alcohol to acetaldehyde. This leads to the accumulation of acetaldehyde in the blood.
The ALDH2 (rs671) SNP produces an inactive enzyme with a reduced ability to clear acetaldehyde from the body. Individuals with the ALDH2 variant SNP have a reduced risk of alcoholism and will develop hangover symptoms from a smaller amount of alcohol. In some genotypes, the risk of adverse health outcomes such as oesophageal cancer increases with alcohol consumption.
{{vm.outcome}} sensitivity to alcohol
ADH1B {{vm.details.Genes.ADH1B | alleles : '/' }}
ALDH2 {{vm.details.Genes.ALDH2 | alleles : '/' }}
1. Zhang GH, Mai RQ, Huang B. Meta-analysis of ADH1B and ALDH2 polymorphisms and esophageal cancer risk in China. World J Gastroenterol 2010; 16(47): 6020-5.
2. Yokoyama M, Yokoyama A, Yokoyama T, et al. Hangover susceptibility in relation to aldehyde dehydrogenase-2 genotype, alcohol flushing, and mean corpuscular volume in Japanese workers. Alcoholism, clinical and experimental research 2005; 29(7): 1165-71.
3. Chen CC, Lu RB, Chen YC, et al. Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. Am J Hum Genet 1999; 65(3): 795-807.
4. Guo H, Zhang G, Mai R. Alcohol dehydrogenase-1B Arg47His polymorphism and upper aerodigestive tract cancer risk: a meta-analysis including 24,252 subjects. Alcoholism, clinical and experimental research 2012; 36(2): 272-8.
5. Chuang SC, Agudo A, Ahrens W, et al. Sequence Variants and the Risk of Head and Neck Cancer: Pooled Analysis in the INHANCE Consortium. Front Oncol 2011; 1: 13.
6. Zhang G, Mai R, Huang B. ADH1B Arg47His polymorphism is associated with esophageal cancer risk in high-incidence Asian population: evidence from a meta-analysis. PLoS One 2010; 5(10): e13679.
We have developed a ratings system so that you can see our level of confidence in the research that we have used as a basis for our recommendations. This is based on Oxford Centre for Evidence Based Medicine – Level of Evidence, March 2009* and has been modified by myDNA to apply for genetic tests.
| Level | Causation and treatment |
|---|---|
| ★★★★★ |
|
| ★★★★ |
|
| ★★★ |
|
| ★★ |
|
| ★ |
|
*http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/